Registry for Neuroendocrine Tumours in Switzerland

SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland

Insel Gruppe AG, University Hospital Bern · NCT01039922

This study is collecting health information from patients with rare gastroentero-pancreatic neuroendocrine tumors in Switzerland to see how different treatments work and improve care for these patients.

Quick facts

Study typeObservational
Enrollment1245 (estimated)
SexAll
SponsorInsel Gruppe AG, University Hospital Bern (other)
Locations55 sites (Aarau and 54 other locations)
Trial IDNCT01039922 on ClinicalTrials.gov

What this trial studies

This registry aims to systematically collect clinical information from patients diagnosed with gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) in Switzerland. By gathering data from various hospitals and general practitioners, the study seeks to improve understanding of GEP-NETs, which are rare and often challenging to manage due to limited treatment options. The data will be anonymized and entered into a specially designed database, allowing for the evaluation of treatment strategies and patient outcomes over time. The initiative is crucial for addressing the current gaps in knowledge and variability in treatment approaches across the country.

Who should consider this trial

Good fit: Ideal candidates for this registry are patients diagnosed with neuroendocrine tumors in Switzerland who can provide informed consent.

Not a fit: Patients with neuroendocrine tumors diagnosed outside of Switzerland or those who cannot provide informed consent may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with neuroendocrine tumors.

How similar studies have performed: Other registries focusing on rare tumors have shown success in improving patient outcomes and treatment strategies, indicating that this approach is promising.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Neuroendocrine tumor irrespective of primary tumor location
* Diagnosis in Switzerland
* Given informed consent

Where this trial is running

Aarau and 54 other locations

+5 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Neuroendocrine Tumors, Carcinoid Tumor, Registries

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.